Pharmaceuticals set to outperform: Insync
The pharmaceutical sector is likely to see increased growth and profitability in coming years, argues Insync Funds Management.
The pharmaceutical sector is likely to see increased growth and profitability in coming years, argues Insync Funds Management.
The oil price is likely to fall to around $30 to $50 per barrel in the short term, argues GMO investment...
Emerging markets got off to a slow start in 2015, with Russia and Brazil the worst performers, according to HSBC.
Global equity exchange-traded funds (ETFs) experienced strong trading volumes in 2014 while trading in large Australian equity ETFs declined, says...
The managers of the $109 billion Future Fund have been quietly accumulating cash since September 2014, citing "uncertainty around the...
The recent rate cut by the RBA has reinforced Credit Suisse’s view that Australian equities will provide positive returns in...
Initial public offerings backed by private equity have outperformed non-private equity floats since 2013, according to a new report commissioned...
Tokyo-based Nikko Asset Management is still holding the Japanese equity market in high favour in 2015 as it awaits the...
It will be a "tricky year" for investors as market volatility and a tough equity market combine to create a...
The Australian Council of Superannuation Investors (ACSI) has called on ASX 200 companies to increase their female board representation to...
Global dividends surged to a record US$518.7 billion in Q3 2025, up 6.2% year-on-year, with financials leading the way. The...
Over the past 15 years, middle market direct lending has grown into one of the most dynamic areas of alternative...
For most Australians, superannuation is their largest financial asset outside the family home. So, when it comes to digital security,...
In financial markets, drama makes headlines. Share prices surge, tumble, and rebound — creating the stories that capture attention. But...
